A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T

Abroad (travel likely)RecruitingPHASE2

Conditions

Large B-cell Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University Health Network (UHN), Toronto, Ontario, Canada
Contact: Study coordinator (John Kuruvilla, FRCPC) · LymphomaClinicalTrials@uhn.ca · 4169462821
Contact: Principal Investigator (John Kuruvilla, FRCPC)

Study leads

John Kuruvilla, FRCPC
Principal Investigator
University Health Network, Toronto

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

Diffuse Large B-cell Lymphoma Refractory · Refractory Primary Mediastinal Large B-Cell Lymphoma · Refractory Transformed B-cell Non-Hodgkin Lymphoma

Abroad (travel likely)RecruitingPHASE2

Créteil, France · Dijon, France

R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse

Diffuse Large B-cell Lymphoma

Abroad (travel likely)RecruitingPHASE2

Shanghai, China · Ürümqi, China

Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients

Relapsed Large B-cell Lymphoma · Refractory Large B-cell Lymphoma · Diffuse Large B-cell Lymphoma (DLBCL)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Seoul, South Korea

The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study

Large B-cell Lymphoma · TP53

Abroad (travel likely)RecruitingPHASE2

Nanjing, China